Skip to main content
. 2020 Jan 11;2020:9505312. doi: 10.1155/2020/9505312

Table 5.

Comparisons of percent values of patients with CCL17 levels > 549.0 pg/mL or anti‐BP180 > 60 U/mL in the two groups of patients with different miR-1291 levels.

Serum miR-1291 n CCL17 > 549 pg/mLn (%) Anti‐BP180 > 60 U/mL, n (%)
>0.31 23 22 (95.65) 15 (65.22)
≤0.31 22 12 (54.55) 7 (31.82)
P 0.001 0.025